St. Jude Neuromodulation draws warning letter
This article was originally published in The Gray Sheet
FDA warning letter dated July 1 cites non-conformities with current good manufacturing practices at St. Jude's Neuromodulation division facilities in Plano, Tex., and Hackettstown, N.J., which were observed during FDA inspections in March and April. St. Jude says it has already begun addressing the issues, which pertain to manufacturing process and documentation issues, and not specific device deficiencies, according to the company. FDA says it will not approve any St. Jude Neuromodulation PMA application until the warning letter is resolved. But St. Jude notes that it does not have any major neuromodulation device filings pending. The company recently completed enrollment of a pivotal study of its Libra and LibraXP deep brain stimulation systems for symptomatic Parkinson's disease. The company says it expects to file a PMA for the indication in about 18 months
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.